Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems

Journal of Biomedical Materials Research - Part A

Volumn 94, Issue 2, 2010, Pages 476-484

  Patel, Ravi B ^a   Carlson, Angela N ^a   Solorio, Luis ^a   Exner, Agata A ^b  

^a Case Western Reserve University   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biodegradable polymers; Cancer chemotherapy; Controlled release; In situ forming implant; Phase inversion

Indexed keywords

BIODEGRADABLE POLYMERS; CHEMOTHERAPY; DISSOLUTION; MOLECULAR WEIGHT; POLYMER BLENDS; SOLUBILITY;

ADJUVANT CHEMOTHERAPY; BURST RELEASE; CANCER CHEMOTHERAPY; CANCER THERAPY; CONTROLLED RELEASE; D , L-LACTIDE; DRUG LOADING; DRUG RELEASE; HIGH MOLECULAR WEIGHT; IN-SITU FORMING; LITTLE RESEARCH; LOW MOLECULAR WEIGHT DRUGS; MINIMALLY INVASIVE; MODEL DRUGS; PHASE INVERSION; PYRROLIDINONE; SIGNIFICANT FACTORS; SOLUBILITY STUDIES; THERMAL ABLATION; WATER CONCENTRATIONS;

CONTROLLED DRUG DELIVERY;

1 METHYL 2 PYRROLIDINONE; EXCIPIENT; FLUORESCEIN SODIUM; POLOXAMER; POLYGLACTIN; POLYMER; WATER; ANTINEOPLASTIC AGENT; BIOMATERIAL; DRUG CARRIER; FLUORESCEIN; FLUORESCENT DYE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ARTICLE; BIODEGRADABILITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; IMPLANT; IN SITU FORMING IMPLANT; MOLECULAR WEIGHT; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; STRUCTURE ANALYSIS; CHEMISTRY; DRUG FORMULATION; HUMAN; MATERIALS TESTING; METABOLISM; NEOPLASMS; PROCEDURES; PROSTHESES AND ORTHOSES;

ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EXCIPIENTS; FLUORESCEIN; FLUORESCENT DYES; HUMANS; LACTIC ACID; MATERIALS TESTING; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR WEIGHT; NEOPLASMS; POLYGLYCOLIC ACID; PROSTHESES AND IMPLANTS; WATER;

EID: 77953820034     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32724     Document Type: Article

References (31)

1. Laurencin CT, Langer R. Polymeric controlled release systems: new methods for drug delivery. Clin Lab Med 1987;7:301-323. (Pubitemid 17113981)
2. Dash AK, Cudworth GC. Therapeutic applications of implantable drug delivery systems. J Pharmacol Toxicol Methods 1998;40:1-12.
3. Exner AA, Saidel GM. Drug-eluting polymer implants in cancer therapy. Expert Opin Drug Deliv 2008;5:775-788.
4. Weinberg BD, Blanco E, Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 2008;97:1681-1702.
5. Saltzman WM, Fung LK. Polymeric implants for cancer chemotherapy. Adv Drug Deliv Rev 1997;26:209-230.
6. Qian F, Saidel GM, Sutton DM, Exner A, Gao J. Combined modeling and experimental approach for the development of dualrelease polymer millirods. J Control Release 2002;83:427-435.
7. Qian F, Nasongkla N, Gao J. Membrane-encased polymer millirods for sustained release of 5-fluorouracil. J Biomed Mater Res A 2002;61:203-211.
8. Bernatchez SF, Merkli A, Minh TL, Tabatabay C, Anderson JM, Gurny R. Biocompatibility of a new semisolid bioerodible poly(ortho ester) intended for the ocular delivery of 5-fluorouracil. J Biomed Mater Res 1994;28:1037-1046. (Pubitemid 24274845)
9. Berrada M, Yang Z, Lehnert S. Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments. Int J Radiat Oncol Biol Phys 2002;54:1550-1557.
10. Brem H, Gabikian P. Biodegradable polymer implants to treat brain tumors. J Control Release 2001;74:63-67.
11. Fleming AB, Saltzman WM. Pharmacokinetics of the carmustine implant. Clin Pharmacokinet 2002;41:403-419.
12. Weinberg BD, Ai H, Blanco E, Anderson JM, Gao J. Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J Biomed Mater Res A 2007;81:161-170.
13. Au JL, Jang SH, Zheng J, Chen CT, Song S, Hu L, Wientjes MG. Determinants of drug delivery and transport to solid tumors. J Control Release 2001;74:31-46.
14. Strasser JF, Fung LK, Eller S, Grossman SA, Saltzman WM. Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther 1995;275:1647-1655. (Pubitemid 26129958)
15. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-592.
16. Weinberg BD, Patel RB, Wu H, Blanco E, Barnett CC, Exner AA, Saidel GM, Gao J. Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants. Med Biol Eng Comput 2008;46:1039-1049.
17. Weinberg BD, Blanco E, Lempka SF, Anderson JM, Exner AA, Gao J. Combined radiofrequency ablation and doxorubicin-eluting polymer implants for liver cancer treatment. J Biomed Mater Res A 2007;81:205-213.
18. Krupka TM, Weinberg BD, Ziats NP, Haaga JR, Exner AA. Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat. Invest Radiol 2006;41:890-897.
19. Dunn RL, English JP, Cowsar DR, Vanderbilt DP. Biodegradable in-situ forming implants and methods of producing the same. US Patent No. 4,938,763. 1990.
20. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61(2Suppl 1):25-31.
21. McHugh AJ. The role of polymer membrane formation in sustained release drug delivery systems. J Control Release 2005;109:211-221.
22. Astaneh R, Erfan M, Moghimi H, Mobedi H. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior. J Pharm Sci 2009;98:135-145.
23. Ravivarapu HB, Moyer KL, Dunn RL. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm 2000;194:181-191.
24. Brodbeck KJ, DesNoyer JR, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer. J Control Release 1999;62:333-344.
25. DesNoyer JR, McHugh AJ. The effect of pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release 2003;86:15-24.
26. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002;41:485-504.
27. Pean JM, Venier-Julienne MC, Boury F, Menei P, Denizot B, Benoit JP. NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J Control Release 1998;56:175-187.
28. Graham PD, Brodbeck KJ, McHugh AJ. Phase inversion dynamics of PLGA solutions related to drug delivery. J Control Release 1999;58:233-245.
29. Eliaz RE, Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J Biomed Mater Res 2000;50:388-396.
30. Luan X, Bodmeier R. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems. J Control Release 2006;110:266-272. (Pubitemid 41827479)
31. Jaraswekin S, Prakongpan S, Bodmeier R. Effect of poly(lactideco- glycolide) molecular weight on the release of dexamethasone sodium phosphate from microparticles. J Microencapsul 2007;24:117-128.